The art and science of running a successful pharmaceutical company.
September 9, 2009
By:George Koroneos, Online Content & News Editor
With the pending retirement of three senior-level executives, Roche announced a new corporate executive team to bridge the personnel gap while the company looks for new leaders.
 |
May 7, 2009
By:George Koroneos, Online Content & News Editor
As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.
|
April 8, 2009
By:Jeff Gilbreth, Fred Kelly
A company’s trade secrets and the goodwill it has developed can mean the difference between a blockbuster and a failure. Here’s what you should know and do to properly negotiate post-employment agreements.
|
April 8, 2009
By:George Koroneos, Online Content & News Editor
Just two months after the purchase of Wyeth, Pfizer breaks its research division into two—one for large molecules and vaccines, and another for small molecules—with Wyeth and Pfizer execs at the helms.
|
April 1, 2009
By:George Koroneos, Online Content & News Editor
Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose.
|
April 1, 2009
By:George Koroneos, Online Content & News Editor
Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
